Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study: Femara provides survival advantage vs. tamoxifen in adjuvant treatment
February 24th, 2005
Adjuvant use of Femara (letrozole tablets) in postmenopausal women with hormone receptor-positive early breast cancer demonstrated a significant 19% reduction in risk of relapse (p=0.003), especially reducing the risk that the cancer would spread to other parts of the body (distant metastases) by 27%, compared with the reductions offered by tamoxifen (p=0.006), according to an independent, international study presented by the International Breast Cancer Study Group. The data, from the Breast International Group (BIG) 1-98 trial, result from a head-to-head comparison of Femara with tamoxifen in more than 8000 women treated at a median follow-up of 26 months. ...
Source: Women's Health Weekly (2005-02-24)
|
